Skip to content

Internet Explorer is no longer supported by this website.

For optimal browsing we recommend using Chrome, Firefox or Safari.
Heart icon (animated) heart icon (static)
Our Initiatives
Explore more Johnson & Johnson sites:
A graphic of the flag of Australia alt
A graphic of the flag of Argentina alt
A graphic of the flag of Brazil alt
A graphic of the national flag of Canada alt
A graphic of the flag of Chile alt
A graphic of the national flag of the People's Republic of China alt
A graphic of the national flag of Colombia alt
A graphic of the national flag of Ecuador alt
A graphic of the flag of Germany alt
A graphic of the national flag of India alt
A graphic of the national flag of Japan alt
A graphic of the flag of Mexico alt
A graphic of the flag of Paraguay alt
A graphic of the flag of Peru alt
A graphic of the flag of Russia alt
Switzerland
A graphic of the flag of Switzerland alt
A graphic of the national flag of Uruguay alt
A graphic of the flag of Venezuela alt
Share
Click the heart to show your support of this pledge.
Empty Heart Icon
457
Latest News

Johnson & Johnson Signs a Historic Pledge to Uphold the Integrity of the Scientific Process in Developing an Investigational COVID-19 Vaccine

Share
Click the heart to show your support of this pledge.
Empty Heart Icon
457
In signing the pledge, we are joining eight other biopharmaceutical companies working on vaccine research and development in making the safety and well-being of vaccinated individuals our top priority.
Today's Top Reads Close

Today Johnson & Johnson is announcing that we, alongside eight other companies working on investigational COVID-19 vaccines, are signing a #WeStandWithScience pledge committed to upholding the integrity of the scientific process as we work towards potential global regulatory filings and approvals of the first vaccines for COVID-19.

In signing the pledge, Johnson & Johnson, AstraZeneca, BioNTech, GlaxoSmithKline, Merck, Moderna, Inc., Novavax, Inc., Pfizer Inc. and Sanofi are underscoring a united commitment to develop and test potential vaccines for COVID-19 in accordance with high ethical standards and sound scientific principles regarding the conduct of our clinical trials and the rigor of our manufacturing processes.

As part of the pledge, the companies will continue to make the safety and well-being of vaccinated individuals their top priority, as well as work to ensure a sufficient supply and range of vaccine options, including those suitable for global access.

The companies also pledge to only submit their vaccines for approval or emergency use authorization after demonstrating safety and efficacy through a Phase 3 clinical study that is designed and conducted to meet the requirements of expert regulatory authorities.

To read more about the pledge, and why we believe rigorous science and safety must be the priority in vaccine development, go here.

Click the heart to show your support of this pledge.
Empty Heart Icon
457
Live Video Series
The Road to a Vaccine
In Season 3 of The Road to a Vaccine, host Lisa Ling returns to interview scientists, global healthcare leaders and other experts about the way COVID-19 vaccines are being distributed, how they will help change life as we now know it—and what’s being done about the persistent health inequities that the pandemic has exposed.
Season 3 Preview
Returning Down the Road to a COVID-19 Vaccine

More from Johnson & Johnson

This site uses cookies as described in our Cookie Policy. Please click the "Accept" button or continue to use our site if you agree to our use of cookies.
Close cookie banner icon
You are now leaving jnj.com. The site you’re being redirected to is a branded pharmaceutical website. Please click below to continue to that site.
Continue